Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Decrease in Short Interest

Xenetic Biosciences Inc (NASDAQ:XBIO) was the target of a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 1,700 shares, a drop of 22.7% from the March 15th total of 2,200 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 6,100 shares, the short-interest ratio is presently 0.3 days.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC raised its holdings in Xenetic Biosciences Inc (NASDAQ:XBIO) by 24.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 143,400 shares of the company’s stock after purchasing an additional 28,300 shares during the period. Renaissance Technologies LLC owned 0.95% of Xenetic Biosciences worth $41,000 at the end of the most recent reporting period. Institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Stock Down 2.3 %

XBIO opened at $4.33 on Monday. The company has a market capitalization of $6.67 million, a price-to-earnings ratio of -1.57 and a beta of 2.60. The firm has a 50-day moving average price of $4.06 and a 200-day moving average price of $3.74. Xenetic Biosciences has a twelve month low of $2.55 and a twelve month high of $5.97.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.